{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:59:16Z","timestamp":1791377956798,"version":"4.3.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40272-023-00600-y","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T12:01:26Z","timestamp":1700913686000},"page":"95-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cantharidin Topical Solution 0.7%: First Approval"],"prefix":"10.1007","volume":"26","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"600_CR1","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s13555-022-00826-7","volume":"12","author":"F Lacarrubba","year":"2022","unstructured":"Lacarrubba F, Micali G, Trecarichi AC, et al. New developing treatments for molluscum contagiosum. Dermatol Ther (Heidelb). 2022;12:2669\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"600_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40257-020-00570-8","volume":"22","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Siegfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating VP-102, a drug-device combination product containing cantharidin 0.7% (w\/v) for the treatment of molluscum contagiosum. Am J Clin Dermatol. 2021;22(2):257\u201365.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"600_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13555-021-00576-y","volume":"11","author":"S Guenthner","year":"2021","unstructured":"Guenthner S, McFalda W, Kwong P, et al. COVE-1: a phase 2, open-label study to evaluate efficacy and safety and the optimal regimen of VP-102, a proprietary drug-device product containing topical cantharidin (0.7% w\/v) under occlusion for the treatment of common warts. Dermatol Ther (Heidelb). 2021;11(5):1623\u201334.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"600_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40257-018-0375-4","volume":"19","author":"PP Vakharia","year":"2018","unstructured":"Vakharia PP, Chopra R, Silverberg NB, et al. Efficacy and safety of topical cantharidin treatment for molluscum contagiosum and warts: a systematic review. Am J Clin Dermatol. 2018;19(6):791\u2013803.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"600_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.36849\/JDD.7230","volume":"22","author":"H Han","year":"2023","unstructured":"Han H, Smythe C, Yousefian F, et al. Molluscum contagiosum virus evasion of immune surveillance: a review. J Drugs Dermatol. 2023;22(2):182\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"600_CR6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1001\/jamadermatol.2020.3238","volume":"156","author":"LF Eichenfield","year":"2020","unstructured":"Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w\/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(12):1315\u201323.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"600_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.36849\/JDD.5626","volume":"20","author":"S Niazi","year":"2021","unstructured":"Niazi S, Brabec B, Anschutz L, et al. A phase 2 open-label study to evaluate VP-102 for the treatment of molluscum contagiosum. J Drugs Dermatol. 2021;20(1):70\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"600_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ijd.14079","volume":"57","author":"A Guzman","year":"2018","unstructured":"Guzman A, Schairer D, Garelik J, et al. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. Int J Dermatol. 2018;57(8):1001\u20136.","journal-title":"Int J Dermatol"},{"issue":"2","key":"600_CR9","first-page":"27","volume":"12","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Kircik L. Topical cantharidin in the management of molluscum contagiosum: preliminary assessment of an ether-free, pharmaceutical-grade formulation. J Clin Aesthet Dermatol. 2019;12(2):27\u201330.","journal-title":"J Clin Aesthet Dermatol"},{"key":"600_CR10","unstructured":"US Food & Drug Administration. Bulk drug substances nominated for use in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act. 2023. https:\/\/www.fda.gov\/media\/94164\/download. Accessed 1 Sept 2023."},{"key":"600_CR11","unstructured":"Cohen SR. Safety and efficacy of topical cantharidin for the treatment of molluscum contagiosum, phase 2 trial (NCT03017846). 2017. https:\/\/www.clinicaltrials.gov\/. Accessed 21 Sept 2023."},{"key":"600_CR12","unstructured":"Verrica Pharmaceuticals Inc. YCANTH\u2122 (cantharidin) topical solution, 0.7%: US prescribing information. 2023. https:\/\/ycanth.com\/. Accessed 15 Aug 2023."},{"key":"600_CR13","unstructured":"Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals announces FDA approval of YCANTHTM (cantharidin) topical solution as the first FDA approved treatment of pediatric and adult patients with molluscum contagiosum [media release]. 21 Jul 2023. https:\/\/www.verrica.com."},{"key":"600_CR14","unstructured":"US Food & Drug Administration. FDA approves first treatment for molluscum contagiosum [media release]. 24 Jul 2023. https:\/\/www.fda.gov\/."},{"key":"600_CR15","unstructured":"Verrica Pharmaceuticals Inc. Verrica Pharmaceuticals reports second quarter 2023 financial results [media release]. 8 Aug 2023. https:\/\/verrica.com\/."},{"key":"600_CR16","unstructured":"Torii Pharmaceutical. Torii has entered into license agreement with Verrica Pharmaceuticals to develop & commercialize VP-102 in Japan [media release]. 17 Mar 2021. https:\/\/www.torii.co.jp\/."},{"key":"600_CR17","unstructured":"Verrica Pharmaceuticals Inc. Form 10-K. 2023. https:\/\/verrica.com\/sec_filings\/0000950170-23-006118\/. Accessed 4 Sept 2023."},{"issue":"2","key":"600_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2133.1988.tb01769.x","volume":"118","author":"B Bertaux","year":"1988","unstructured":"Bertaux B, Prost C, Heslan M, et al. Cantharide acantholysis: endogenous protease activation leading to desmosomal plaque dissolution. Br J Dermatol. 1988;118(2):157\u201365.","journal-title":"Br J Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-023-00600-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T09:21:20Z","timestamp":1704446480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-023-00600-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s40272-023-00600-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]},"assertion":[{"value":"25 November 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article on the US development of the agent. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}